Rethinking heart-lung support: We focus on the essential requirements of patients and their treating physicians in situations where extracorporeal support is critical. With our innovations and solutions, we redefine the field of Extracorporeal Life Support (ECLS and ECMO) – full attention, strict focus, easy access.
We are Hemovent. At the heart of what matters.
Human circulation delivers the blueprint for Hemovent’s proprietary Bionique Flow Technologies which target to perform extracorporeal perfusion and oxygenation with the utmost care and least impact on natural blood and cell physiology with the following goals:
Minimize sheer stress.
With our Bionique Flow Technologies we maximize patient care and enable clinicians to apply life-saving technologies safely and easy to use.
Hemovent’s Bionique Flow Technologies offer a whole variety of opportunities to enhance safety, efficacy, performance and ease of use which result in unique solutions in the field of ECMO and ECLS.
Built on Hemovent’s proprietary Bionique Flow Technologies, the MOBYBOX is a miniaturized heart-lung machine. As a self-contained and fully integrated Extracorporeal Life Support (ECLS) system it is designed with an ultimate focus on safety, ease of use, mobility, and performance for heart and lung support.
ECLS patients are found in multiple treatment settings which calls for flexible system configurations. The pneumatic power supply of the MOBYBOX system allows for an easy separation of the patient unit from the controller and therefore offers an unrivaled versatility.
The patient unit can be directly attached to the patient’s bedside and always stays with the patient even during prone positioning and mobilization. The Master control can be placed independently and includes back-up safety and full gas blender capabilities.
Without requiring any electrical power source, the MOBYBOX is ideally suited for situations with limited infrastructure such as emergency applications in the field or during transport. The ultra-small Runner control will combine an unrivaled mobility with the safety from ease of use.
* Conformity assessment according to Medical Device Directive 93/42/EEC for these products have not been completed and products are currently not commercially available in the EU.
Products currently not available for distribution or sale in the US or internationally outside the EU.
About 2.2mn patients worldwide are suffering from acute cardiac and respiratory failure and the numbers of ECMO and ECLS deployments have been growing rapidly in the recent time.
With their patented artificial lung and heart support technology and manufacturing platform, Hemovent caters to the demands of this growing market.
Hemovent is backed by a consortium of institutional investors.